Wagner Tyer D, Westrich Kimberly D, Nordyke Robert J, Campbell Jon D
National Pharmaceutical Council, Washington, DC, USA.
Petauri, LLC, Formerly National Pharmaceutical Council, Washington, DC, USA.
J Med Econ. 2024 Jan-Dec;27(1):1537-1541. doi: 10.1080/13696998.2024.2428109. Epub 2024 Dec 3.
The Institute for Clinical and Economic Review (ICER) publishes annual Unsupported Price Increase (UPI) reports on prescription drugs, which have gained attention from policymakers and healthcare stakeholders. These reports do not adjust for inflation in their analyses of net price changes. This study aimed to evaluate the economic context of reported drug price increases in ICER's UPI reports by applying inflation adjustments to the estimated impact on healthcare spending.
Separate inflation adjustments using the Medical Consumer Price Index (Medical CPI) and the Consumer Price Index for All Urban Consumers (CPI-U) were applied to unadjusted UPI findings. The study analyzed data from four most recent UPI reports spanning pricing data from 2018 to 2019 (report year 2020) to 2021 to 2022 (report year 2023), focusing on drugs classified as having "unsupported" price increases.
Inflation-adjusted analyses showed lower estimates of real changes in spending compared to ICER's unadjusted figures across all drugs analyzed. Across the four UPI reports, the average report-year difference in Medical CPI inflation adjustment spending versus unadjusted findings was 53%, whereas the average report-year difference in CPI-U inflation adjustment spending versus unadjusted findings was 80%. In the most recent report year of 2023, ICER's unadjusted estimate of a $1.3 billion increase in healthcare spending transformed to a $134 million decrease when adjusted by Medical CPI and a $1.51 billion decrease when adjusted by CPI-U.
This study demonstrates that inflation adjustment can alter not only the findings but also the interpretation of drug spending changes in UPI reports. The findings highlight the importance of considering economic context in evaluating drug pricing trends and suggest that unadjusted figures may overstate the impact of real price changes. Given the influence of these reports on policy discussions, incorporating inflation adjustments into analyses is one of many steps toward informing evidence-based policy decisions.
临床与经济评论研究所(ICER)发布关于处方药的年度无支撑价格上涨(UPI)报告,这些报告已引起政策制定者和医疗保健利益相关者的关注。这些报告在分析净价格变化时未对通货膨胀进行调整。本研究旨在通过对医疗保健支出的估计影响应用通货膨胀调整,评估ICER的UPI报告中所报告的药品价格上涨的经济背景。
使用医疗消费者价格指数(医疗CPI)和所有城市消费者消费者价格指数(CPI-U)分别进行通货膨胀调整,应用于未调整的UPI结果。该研究分析了最近四份UPI报告的数据,涵盖从2018年至2019年(报告年份2020年)到2021年至2022年(报告年份2023年)的定价数据,重点关注被归类为有“无支撑”价格上涨的药品。
与ICER对所有分析药物的未调整数据相比,经通货膨胀调整的分析显示支出实际变化的估计值较低。在这四份UPI报告中,医疗CPI通货膨胀调整支出与未调整结果之间的平均报告年份差异为53%,而CPI-U通货膨胀调整支出与未调整结果之间的平均报告年份差异为80%。在2023年最近的报告年份中,ICER对医疗保健支出增加13亿美元的未调整估计,在经医疗CPI调整后变为减少1.34亿美元,经CPI-U调整后变为减少15.1亿美元。
本研究表明,通货膨胀调整不仅可以改变UPI报告中药物支出变化的结果,还可以改变其解释。研究结果突出了在评估药品定价趋势时考虑经济背景的重要性,并表明未调整的数据可能高估了实际价格变化的影响。鉴于这些报告对政策讨论的影响,将通货膨胀调整纳入分析是朝着基于证据的政策决策提供信息的众多步骤之一。